Literature DB >> 1721389

Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.

M Winkler1, U Jost, B Ringe, G Gubernatis, K Wonigeit, R Pichlmayr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721389

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  11 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

2.  Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

Authors:  Markus Bickel; Evrim Anadol; Martin Vogel; Wolf Peter Hofmann; Nils von Hentig; Johannes Kuetscher; Michael Kurowski; Christian Moench; Tessa Lennemann; Thomas Lutz; Wolf Otto Bechstein; Hans Reinhard Brodt; Jürgen Rockstroh
Journal:  J Antimicrob Chemother       Date:  2010-03-04       Impact factor: 5.790

3.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.

Authors:  Y Böttiger; C Brattström; G Tydén; J Säwe; C G Groth
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 4.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

5.  Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Authors:  Gwenn E McLaughlin; Michelle Schober; Maria Perez; Phillip Ruiz; Bernard W Steele; Carolyn Abitbol
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 6.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

8.  Factors affecting variability in distribution of tacrolimus in liver transplant recipients.

Authors:  H Zahir; G McCaughan; M Gleeson; R A Nand; A J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

9.  Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA).

Authors:  A K Gonschior; U Christians; F Braun; M Winkler; A Linck; J Baumann; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.